Pallas Capital Advisors LLC Has $11.33 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

Pallas Capital Advisors LLC boosted its position in Eli Lilly and Company (NYSE:LLYFree Report) by 2.4% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 19,441 shares of the company’s stock after purchasing an additional 453 shares during the period. Pallas Capital Advisors LLC’s holdings in Eli Lilly and Company were worth $11,332,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Norges Bank bought a new position in Eli Lilly and Company in the 4th quarter valued at about $3,416,206,000. Moneta Group Investment Advisors LLC raised its holdings in Eli Lilly and Company by 102,752.2% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 5,446,026 shares of the company’s stock valued at $1,992,374,000 after acquiring an additional 5,440,731 shares during the period. Morgan Stanley raised its holdings in Eli Lilly and Company by 44.1% in the 4th quarter. Morgan Stanley now owns 12,059,204 shares of the company’s stock valued at $4,411,740,000 after acquiring an additional 3,691,436 shares during the period. Imprint Wealth LLC raised its holdings in Eli Lilly and Company by 53,716.8% in the 2nd quarter. Imprint Wealth LLC now owns 1,751,200 shares of the company’s stock valued at $175,120,000 after acquiring an additional 1,747,946 shares during the period. Finally, T. Rowe Price Investment Management Inc. bought a new position in Eli Lilly and Company in the 4th quarter valued at about $445,944,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

LLY has been the topic of several recent research reports. Bank of America raised their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $815.00 target price on shares of Eli Lilly and Company in a report on Monday. Truist Financial reaffirmed a “buy” rating and set a $850.00 target price on shares of Eli Lilly and Company in a report on Friday, March 22nd. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Finally, BMO Capital Markets raised their target price on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a report on Wednesday, February 7th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $689.52.

Read Our Latest Research Report on Eli Lilly and Company

Insider Buying and Selling

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the transaction, the insider now owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In the last 90 days, insiders have sold 195,055 shares of company stock valued at $125,254,657. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $759.93 on Tuesday. The firm’s 50 day simple moving average is $739.63 and its 200 day simple moving average is $641.00. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The firm has a market capitalization of $722.06 billion, a PE ratio of 131.02, a price-to-earnings-growth ratio of 1.71 and a beta of 0.34. Eli Lilly and Company has a 1-year low of $342.30 and a 1-year high of $800.78.

Eli Lilly and Company (NYSE:LLYGet Free Report) last posted its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. The business had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. Eli Lilly and Company’s revenue was up 28.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.09 EPS. As a group, analysts expect that Eli Lilly and Company will post 12.42 earnings per share for the current fiscal year.

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Recommended Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.